共 332 条
[1]
Chao MP(2013)Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma—novel and emerging therapies Cancer Manag Res 5 251-269
[2]
Bron D(2017)Unmet needs in the scientific approach to older patients with lymphoma Haematologica 102 972-975
[3]
Aurer I(2007)Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma Blood 110 616-623
[4]
Andre MPE(2009)Treatment strategies for relapsed and refractory aggressive non-Hodgkin’s lymphoma Expert Opin Pharmacother 10 983-995
[5]
Bonnet C(2013)Antibody-drug conjugates for the treatment of B-cell non-Hodgkin’s lymphoma and leukemia Future Oncol 9 355-368
[6]
Caballero D(2015)Antibody-drug conjugates as novel anti-cancer chemotherapeutics Biosci Rep 35 e00225-3479
[7]
Falandry C(2015)Preclinical pharmacokinetic considerations for the development of antibody drug conjugates Pharm Res 32 3470-1035
[8]
Kimby E(2017)Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review Adv Ther 34 1015-337
[9]
Soubeyran P(2017)Strategies and challenges for the next generation of antibody-drug conjugates Nat Rev Drug Discov 16 315-207
[10]
Zucca E(2018)Antibody-drug conjugates for cancer treatment Annu Rev Med 69 191-2729